Israel’s Redhill Biopharma announced positive top-line results from its Phase III study with RHB-105 for treating Helicobacter pylori (H. pylori) infections. RHB-105 achieved 89.4% efficacy in eradicating H. pylori with no serious adverse events or unexpected safety issues.

http://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1358&PID=0&IID=1947